Primary reason for Medicare Part D premium increase in 2024?
Increased insurer costs due to cap • 25%
General inflation • 25%
Reduced government subsidies • 25%
Other • 25%
Reports and analyses from CMS and health policy experts
Medicare's $2,000 Drug Cost Cap Begins January 1, 2024 Under Inflation Reduction Act
Dec 31, 2024, 12:10 PM
The $2,000 annual cap on out-of-pocket prescription drug costs for Medicare Part D beneficiaries will take effect on January 1, 2024, as part of the Inflation Reduction Act. This cap, designed to reduce financial burdens for seniors, is expected to benefit millions of Americans, with over 3 million enrollees projected to save money in 2025. The law also includes other measures such as a $35 monthly insulin cap, free vaccines for Medicare beneficiaries, and provisions allowing Medicare to negotiate drug prices. Previously, there was no cap on out-of-pocket costs, and beneficiaries faced significant expenses in the catastrophic coverage phase, which had an interim cap of $3,500 in 2024. Medicare Part D covers approximately 53 million beneficiaries. While the cap offers financial relief, insurers are expected to bear more costs, potentially leading to higher premiums. The Biden administration has allocated $5 billion in subsidies to mitigate premium increases. The cap does not apply to medications administered in doctors' offices under Medicare Part B.
View original story
No • 50%
Yes • 50%
No Change • 25%
Increase more than 5% • 25%
Increase up to 5% • 25%
Decrease • 25%
More than 75% • 25%
Less than 25% • 25%
50% to 75% • 25%
25% to 50% • 25%
Ozempic • 25%
Wegovy • 25%
Trelegy Ellipta • 25%
Pomalyst • 25%
21% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
Other • 25%
Diabetes medications • 25%
Cancer treatments • 25%
Chronic condition medications • 25%
Regulatory changes • 25%
Provider withdrawals • 25%
Increased healthcare costs • 25%
Other reasons • 25%
Other • 25%
Rybelsus • 25%
Ozempic • 25%
Wegovy • 25%
Less than $5 billion • 25%
More than $15 billion • 25%
$5 billion to $10 billion • 25%
$10 billion to $15 billion • 25%
Cardiovascular drugs • 25%
Other • 25%
Insulin • 25%
Cancer drugs • 25%